Welcome to LookChem.com Sign In|Join Free

CAS

  • or

98813-70-8

Post Buying Request

98813-70-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

98813-70-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 98813-70-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,8,1 and 3 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 98813-70:
(7*9)+(6*8)+(5*8)+(4*1)+(3*3)+(2*7)+(1*0)=178
178 % 10 = 8
So 98813-70-8 is a valid CAS Registry Number.

98813-70-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-ethynylquinoxaline

1.2 Other means of identification

Product number -
Other names Quinoxaline,2-ethynyl

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:98813-70-8 SDS

98813-70-8Relevant articles and documents

Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform

Desai, Bimbisar,Dixon, Karen,Farrant, Elizabeth,Feng, Qixing,Gibson, Karl R.,Van Hoorn, Willem P.,Mills, James,Morgan, Trevor,Parry, David M.,Ramjee, Manoj K.,Selway, Christopher N.,Tarver, Gary J.,Whitlock, Gavin,Wright, Adrian G.

supporting information, p. 3033 - 3047 (2013/05/22)

Drug discovery faces economic and scientific imperatives to deliver lead molecules rapidly and efficiently. Using traditional paradigms the molecular design, synthesis, and screening loops enforce a significant time delay leading to inefficient use of data in the iterative molecular design process. Here, we report the application of a flow technology platform integrating the key elements of structure-activity relationship (SAR) generation to the discovery of novel Abl kinase inhibitors. The platform utilizes flow chemistry for rapid in-line synthesis, automated purification, and analysis coupled with bioassay. The combination of activity prediction using Random-Forest regression with chemical space sampling algorithms allows the construction of an activity model that refines itself after every iteration of synthesis and biological result. Within just 21 compounds, the automated process identified a novel template and hinge binding motif with pIC50 > 8 against Abl kinase - both wild type and clinically relevant mutants. Integrated microfluidic synthesis and screening coupled with machine learning design have the potential to greatly reduce the time and cost of drug discovery within the hit-to-lead and lead optimization phases.

Synthesis of (η 5-cyclopentadienyl)-1-(4-benzyloxycarbonyl-3,4-dihydroquinoxalin-2- yl)ethene-1,2-dithiolatocobalt(III) and (η 5-cyclopentadienyl)-1-[2-(N,N-dimethylaminomethyleneamino)-3-methyl- 4-oxopteridin-6-yl]ethene-1,2-dithiol

Dinsmore, Andrew,Birks, Jacqueline H.,Garner, C. David,Joule, John A.

, p. 801 - 807 (2007/10/03)

Cobalt(III) complexes are reported in which (a) a dihydroquinoxalinylethenedithiolate ligand models the pyrazine ring oxidation level in Moco, and (b) a pteridinylethenedithiolate models the pteridine ligand in Moco.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 98813-70-8